文献速递中毒与环境急症重症综合管理与镇静镇痛

氟马西尼给药相关不良事件风险低:急性中毒患者的回顾性中毒中心分析

Low risk of adverse events associated with flumazenil administration: a retrospective poison center analysis of acutely poisoned patients.
PubMed 文献 · Clin Toxicol (Phila) · 2025-06-30
一句话结论疑似苯二氮䓬过量患者使用氟马西尼后不良事件发生率低,癫痫发作仅见于有促惊厥共暴露者,慢性苯二氮䓬使用与癫痫无关。

该回顾性研究分析了2012年1月1日至2022年12月31日某州中毒中心报告的286例氟马西尼给药病例。在115例有剂量信息的患者中,不良事件发生23例(20%),最常见为激越16例(13.9%);癫痫发作3例(2.6%),均有促惊厥共暴露(P=0.0128)。慢性苯二氮䓬或非苯二氮䓬镇静催眠药使用161/286例(56.3%),其中发生不良事件15/161例(9.3%)。纳洛酮共给药140/286例(49.0%),其中64/140例(45.7%)意识改善。2例死亡(0.7%)与氟马西尼无关。作者认为,氟马西尼在疑似苯二氮䓬过量患者中不良事件发生率低,可能有助于避免昂贵的诊断评估和有创治疗干预。

要点

  • 286例氟马西尼给药患者中,有剂量信息的115例里不良事件23例(20%),最常见为激越16例(13.9%)。
  • 癫痫发作3例(2.6%),均有促惊厥共暴露(P=0.0128);慢性苯二氮䓬使用161例中不良事件15例(9.3%),与癫痫无关。
  • 纳洛酮共给药140/286例(49.0%),其中64/140例(45.7%)意识改善;2例死亡(0.7%)与氟马西尼无关。
  • 作者认为氟马西尼不良事件发生率低,可能有助于避免昂贵的诊断评估和有创治疗干预。

适用人群与场景

  • 疑似苯二氮䓬过量并接受氟马西尼给药的急性中毒患者,数据来自某州中毒中心2012年1月1日至2022年12月31日的回顾性报告。
  • 慢性苯二氮䓬或非苯二氮䓬镇静催眠药使用者在纳入病例中占161/286例(56.3%)。

红旗征与不能漏的情况

  • 癫痫发作3例(2.6%),均有促惊厥共暴露(P=0.0128)。

研究设计与关键结果

  • 回顾性中毒中心分析,286例氟马西尼给药病例,剂量信息可获取115/286例(40.2%)。
  • 有剂量信息的115例中不良事件23例(20%),最常见为激越16/115例(13.9%)。
  • 癫痫发作3例(2.6%),均有促惊厥共暴露(P=0.0128);慢性苯二氮䓬使用者中不良事件15/161例(9.3%)。
  • 纳洛酮共给药140/286例(49.0%),其中64/140例(45.7%)意识改善;死亡2例(0.7%),与氟马西尼无关。

证据类型、等级与局限

  • 证据类型:回顾性中毒中心病例分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,氟马西尼在疑似苯二氮䓬过量患者中不良事件发生率低,可能有助于避免昂贵的诊断评估和有创治疗干预。
  • 慢性苯二氮䓬使用与癫痫发作无关;癫痫发作仅见于有促惊厥共暴露的患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Benzodiazepine overdose can lead rarely to life-threatening central nervous system and respiratory depression. Flumazenil is a benzodiazepine antagonist. However, reported adverse effects, including seizures and cardiac dysrhythmias, has led some experts to recommend its use only in select populations. Recent studies, however, report low rates of adverse effects. Our objective was to determine the updated incidence of response and adverse effects following flumazenil with or without naloxone.

METHODS: We performed a retrospective review of cases involving flumazenil administration reported to a state poison center between January 1, 2012 and December 31, 2022. The primary outcome was the incidence of adverse effects secondary to flumazenil. Secondary outcomes were associated risk factors, including pro-convulsant co-exposure. We characterized outcomes in cases of naloxone co-administration. The difference in age between groups was compared using the t-test and categorical data was analyzed using Fisher's Exact test. A 2 × 2 table was constructed and 95% confidence intervals for seizures.

RESULTS: Two-hundred eighty-six cases involved flumazenil administration. Dosing information was available for 115/286 (40.2%). Chronic benzodiazepine or non-benzodiazepine sedative-hypnotic use was reported in 161/286 (56.3%). Adverse effects occurred in 23/115 patients (20%) with reported dosing information, the most common being agitation in 16/115 (13.9%). Seizures occurred in three patients (2.6%), all of whom had pro-convulsant co-exposure (P = 0.0128). Most patients with adverse events were chronic benzodiazepine users, 15/161 (9.3%). Naloxone co-administration occurred in 140/286 patients (49.0%) and 64/140 patients (45.7%) who received naloxone had improved mentation. Two deaths (0.7%), not attributable to flumazenil, were reported.

DISCUSSION: Low rates of adverse drug events occurred after flumazenil administration. The occurrence of seizures, regardless of pro-convulsant exposure, was low. Chronic benzodiazepine use was not associated with seizures. This may support the utility of flumazenil in precluding costly diagnostic evaluation and invasive therapeutic interventions.

CONCLUSION: This study suggests a low rate of adverse events following flumazenil administration in patients with suspected benzodiazepine overdose with or without naloxone.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Vohra V, Darling A, Welch R, et al. Low risk of adverse events associated with flumazenil administration: a retrospective poison center analysis of acutely poisoned patients. Clin Toxicol (Phila). 2025. PMID: 40586943. doi:10.1080/15563650.2025.2516130

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。